MCKESSON CORP

Listed Company

MCKCIK 0000927653NYSELarge AcceleratedWholesale-Drugs, Proprietaries & Druggists' SundriesDelawareFY ends Mar 31

Period

FY 2026

Revenue

$403.43B

Net Income

$4.76B

Total Assets

$82.32B

Equity

$-2.17B

Shares Out

120.20M

Op. Cash Flow

$6.16B

Business

McKesson Corp distributes pharmaceuticals and delivers a broad range of healthcare services and supply-chain solutions across the healthcare ecosystem. It offers branded, generic, specialty, biosimilar and OTC drugs, medical‑surgical supplies, technology platforms, logistics, practice management, pharmacy and patient support, specialty pharmacy services, and consulting. The company operates four reportable segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical‑Surgical Solutions, and International. McKesson serves customers through distribution centers, retail and independent pharmacies, hospitals and health systems, specialty practices, biopharma partners, payors, and government channels in the U.S., Canada, and Norway.

Summary from filing dated 2025-05-09

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	Mar 31, 2026 2026-03-31	Mar 31, 2025 2025-03-31	Mar 31, 2024 2024-03-31
Revenues	403,430	359,051	308,951
Cost of sales	388,880	345,728	296,123
Gross profit	14,550	13,323	12,828
Selling, distribution, general, and administrative expenses	8,096	8,507	8,657
Claims and litigation charges, net	3	−108	−147
Restructuring, impairment, and related charges, net	245	286	115
Total operating expenses	8,338	8,901	8,919
Operating income	6,212	4,422	3,909
Other income, net	236	202	132
Interest expense	247	265	252
Income before income taxes	6,201	4,359	3,789
Income tax expense	1,102	878	629
Net income	5,099	3,481	3,160
Net income attributable to noncontrolling interests	337	186	158
Net income attributable to McKesson Corporation	4,762	3,295	3,002
Earnings (loss) per common share attributable to McKesson Corporation	—	—	—
Diluted (in dollars per share)	38.38	25.72	22.39
Basic (in dollars per share)	38.55	25.86	22.54
Weighted-average common shares outstanding	—	—	—
Diluted (in shares)	124	128	134
Basic (in shares)	124	127	133

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	Mar 31, 2026 2026-03-31	Mar 31, 2025 2025-03-31
ASSETS	—	—
Current assets	—	—
Cash and cash equivalents	3,975	5,691
Receivables, net	27,985	25,643
Inventories, net	24,207	23,001
Prepaid expenses and other	1,043	1,063
Total current assets	57,210	55,398
Property, plant, and equipment, net	2,668	2,502
Operating lease right-of-use assets	2,058	1,782
Goodwill	11,316	10,022
Intangible assets, net	4,079	1,464
Other non-current assets	4,992	3,972
Total assets	82,323	75,140
LIABILITIES AND DEFICIT	—	—
Current liabilities	—	—
Drafts and accounts payable	59,973	55,330
Current portion of long-term debt	1,267	1,191
Current portion of operating lease liabilities	287	258
Other accrued liabilities	5,490	4,825
Total current liabilities	67,017	61,604
Long-term debt	5,259	4,463
Long-term deferred tax liabilities	1,330	1,029
Long-term operating lease liabilities	1,801	1,478
Long-term litigation liabilities	5,091	5,601
Other non-current liabilities	2,659	2,659
Commitments and contingent liabilities (Note 17)	—	—
Redeemable noncontrolling interests	943	0
McKesson Corporation stockholders’ deficit	—	—
Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.01 par value, 800 shares authorized, 280 and 279 shares issued at March 31, 2026 and 2025, respectively	3	3
Additional paid-in capital	8,284	8,373
Retained earnings	22,291	17,921
Accumulated other comprehensive loss	−745	−932
Treasury shares, at cost, 160 and 154 shares at March 31, 2026 and 2025, respectively	32,005	27,439
Total McKesson Corporation stockholders’ deficit	−2,172	−2,074
Noncontrolling interests	395	380
Total deficit	−1,777	−1,694
Total liabilities, redeemable noncontrolling interests, and deficit	82,323	75,140

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	Mar 31, 2026 2026-03-31	Mar 31, 2025 2025-03-31	Mar 31, 2024 2024-03-31
OPERATING ACTIVITIES	—	—	—
Net income	5,099	3,481	3,160
Adjustments to reconcile to net cash provided by operating activities:	—	—	—
Depreciation	256	242	253
Amortization	473	394	382
Long-lived asset impairment charges	55	98	43
Deferred taxes	−230	110	603
Charges (credits) associated with last-in, first-out inventory method	−210	82	−157
Non-cash operating lease expense	261	245	228
Loss (gain) from sales of businesses and investments	573	−485	17
Provision for bad debts	100	−130	819
Other non-cash items	−302	−424	−233
Changes in assets and liabilities, net of acquisitions:	—	—	—
Receivables	1,999	3,935	2,954
Inventories	1,082	2,270	1,294
Drafts and accounts payable	4,317	8,301	4,587
Operating lease liabilities	−270	−404	−339
Taxes	−339	−136	331
Litigation liabilities	−684	−401	−395
Other	−219	281	−37
Net cash provided by operating activities	6,155	6,085	4,314
INVESTING ACTIVITIES	—	—	—
Payments for property, plant, and equipment	436	537	431
Capitalized software expenditures	309	322	256
Acquisitions, net of cash, cash equivalents, and restricted cash acquired	3,416	24	272
Proceeds from sales of businesses and investments, net	830	179	47
Other	101	29	160
Net cash used in investing activities	−3,432	−733	−1,072
FINANCING ACTIVITIES	—	—	—
Proceeds from short-term borrowings	9,247	15,086	19,964
Repayments of short-term borrowings	9,247	15,086	19,964
Proceeds from issuances of long-term debt	1,990	498	991
Repayments of long-term debt	1,207	519	288
Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt	0	0	647
Common stock transactions:	—	—	—
Issuances	89	101	116
Share repurchases	4,750	3,146	3,025
Dividends paid	381	345	314
Other	−372	−554	−175
Net cash used in financing activities	−4,631	−3,965	−3,342
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	20	−16	6
Net increase (decrease) in cash, cash equivalents, and restricted cash	−1,888	1,371	−94
Cash, cash equivalents, and restricted cash at end of year	—	—	—
Cash, cash equivalents, and restricted cash at end of year	—	—	—
Less: Restricted cash at end of period included in Other Noncurrent Assets	—	—	—
Less: Restricted cash at end of year included in Prepaid expenses and other	—	—	—
Cash and cash equivalents at end of year	—	—	—
SUPPLEMENTAL CASH FLOW INFORMATION	—	—	—
Interest, net	212	273	234
Income taxes, net of refunds	1,211	1,124	901

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro